Pharmamax Nigeria Limited, an emerging pharmaceutical generic marketing company in Nigeria, plans to invest in broad range of cardiovascular remedies before the end of the year – to enhance patient’s accessibility to anti-hypertensive medicines.
In a related development, the pharmaceutical marketing company says it has concluded arrangements to partner faculties of pharmaceutical sciences in select universities across the country to institute an annual Pharmamax Cardiovascular Academic Awards.
Speaking through the KCH Group Head of Public Communications and New Media, Mr. Morgan Nwanguma recently said the company is spurred by encouragements received from physicians and drugstores across the country on account of efficacy of its Pharmamax brands of Amlodipine and Lisinopril therapies – in restoring health and saving lives of patients across the country.
“The testimonies we are getting especially from physicians in major centres across the country on Pharmamax Amlodipine and Lisinopril is encouraging, and it provides insight into what we need to do next”, he said.
With the acceptability of Calcium Channel Blockers and ACE inhibitors range of anti-hypertensive molecules by patients in the country, Pharmamax says its planned investment in broad ranges is aimed at providing physicians with wider options in prescriptions to varied heart related conditions and also to ensure that the greatest majority of Nigerians in need of these essential medicines are covered.
“Pharmamax has unique understanding of the needs of physicians and patients and that is why we focus on areas of high unmet needs and leverage our expertise to strive for solutions that dramatically improve people’s lives”, Nwanguma added.
Building on a remarkable track record of achievement, he explains that Pharmamax is committed to its mission which is focused on increasing access to a unique range of high quality products for those who need them most.
Giving insight on the Pharmamax Annual Cardiovascular Award, Nwanguma said that his organisation is desirous of encouraging students in pharmaceutical sciences in Nigerian universities especially those who have interest in contributing to on-going research and discussions in cardiovascular related conditions to achieve resounding successes.
He explained that the award which is planned to take effect from next year is designed to recognise outstanding pharmacy students in their final year – that distinguish themselves in providing unique answers to test questions relating to cardiovascular health conditions.
The overall best student, he further disclosed, would be rewarded with handsome cash prize for outstanding performance. Similarly, the Dean, faculty of pharmaceutical sciences of the recipient university will also smile home with a cash reward for his/ her distinguished contribution in moulding excellent minds.
According to Nwanguma, no less than six outstanding students will be rewarded each year primarily to spur pharmacy students into paying more than ample interest in achieving high academic performance and excellence in the field of pharmacy.
Headquartered in Lagos, Pharmamax Nigeria Limited is a member of KCH Group that provides access to a wide range of high-quality patient-centric essential drugs in nearly every therapeutic area, numbering over 50 generics at affordable rates.
On its relationship with regulators and stakeholders in the health sector, the generic marketing company says it enjoys excellent relationship with PCN, NAFDAC and the Ministry of Health because of its pursuit of excellence and compliance in all its operations.
The generics company specifically applauded NAFDAC under the leadership of Prof. Moji Adeyeye for its determined effort to conquer the menace of counterfeit medicines in the country and also the commitment to re-position the regulatory agency for greater heights.